American Journal of Obstetrics & Gynecology
Volume 199, Issue 1 , Pages 26.e1-26.e8 , July 2008

Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States

  • Janet G. Baseman, PhD

      Affiliations

    • Department of Epidemiology, University of Washington, Seattle, WA
    • Corresponding Author InformationReprints: Janet G. Baseman, PhD, MPH, 1107 NE 45th St, Suite 405-F, Seattle, WA 98103.
    • ,
  • Shalini L. Kulasingam, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Duke University, Durham, NC
    • ,
  • Tiffany G. Harris, PhD

      Affiliations

    • New York City Department of Health and Mental Hygiene, New York, NY
    • ,
  • James P. Hughes, PhD

      Affiliations

    • Department of Biostatistics, University of Washington, Seattle, WA
    • ,
  • Nancy B. Kiviat, MD

      Affiliations

    • Department of Pathology, University of Washington, Seattle, WA
    • ,
  • Constance Mao, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Washington, Seattle, WA.
    • ,
  • Laura A. Koutsky, PhD

      Affiliations

    • Department of Epidemiology, University of Washington, Seattle, WA

Received 26 April 2007 ,Accepted 26 November 2007.

References 

  1. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents (vol VII). Lyon, France: IARC; 1997;
  2. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342–362
  3. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists: ACOG Practice Bulletin No.: 61: human papillomavirus. Obstet Gynecol. 2005;105:905–918
  4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;48:6–29
  5. Solomon D, Schiffman M, Tarone R ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293–299
  6. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500–1505
  7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  8. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: international biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 1995;87:796–802
  9. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958–964
  10. Wright TC, Cox JT, Massad LS, et al. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–2129
  11. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749–1757
  12. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439–444
  13. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–2119
  14. Center for devices and Radiological Health, US Food and Drug Administration. Clinical Laboratory Improvement Methods; 2002. Accessed January 14, 2008. Available at: http://wwwn.cdc.gov/clia/chronol/aspy
  15. An introduction to the bootstrap. New York: Chapman and Hall; 1993;436.
  16. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer: the National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer. 1996;73:1001–1005
  17. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871–1876
  18. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619–631
  19. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46–52

 Cite this article as: Baseman JG, Kulasingam SL, Harris TG, et al. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol 2008;199:26.e1-26.e8.

PII: S0002-9378(07)02235-1

doi: 10.1016/j.ajog.2007.11.051

American Journal of Obstetrics & Gynecology
Volume 199, Issue 1 , Pages 26.e1-26.e8 , July 2008

Article Tools